JP2005516938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516938A5 JP2005516938A5 JP2003552781A JP2003552781A JP2005516938A5 JP 2005516938 A5 JP2005516938 A5 JP 2005516938A5 JP 2003552781 A JP2003552781 A JP 2003552781A JP 2003552781 A JP2003552781 A JP 2003552781A JP 2005516938 A5 JP2005516938 A5 JP 2005516938A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- compound
- cancer
- animal
- monosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 150000001875 compounds Chemical group 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- -1 hydroxy, carboxy Chemical group 0.000 claims 6
- 150000002772 monosaccharides Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 4
- 150000002016 disaccharides Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 238000000315 cryotherapy Methods 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 229960000583 acetic acid Drugs 0.000 claims 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000012362 glacial acetic acid Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000003054 hormonal effect Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical group 0.000 claims 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- BZMHXOOEJJRVGM-UHFFFAOYSA-N 1,2-bis(1-methyl-2,3-dihydroindol-2-yl)ethane-1,2-dione Chemical compound C1C2=CC=CC=C2N(C)C1C(=O)C(=O)C1N(C)C2=CC=CC=C2C1 BZMHXOOEJJRVGM-UHFFFAOYSA-N 0.000 claims 1
- JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical compound C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/021,589 US6566341B1 (en) | 2001-12-13 | 2001-12-13 | Derivative of isoindigo, indigo and indirubin for the treatment of cancer |
| US40726702P | 2002-09-03 | 2002-09-03 | |
| PCT/US2002/039866 WO2003051900A1 (en) | 2001-12-13 | 2002-12-13 | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516938A JP2005516938A (ja) | 2005-06-09 |
| JP2005516938A5 true JP2005516938A5 (https=) | 2005-12-22 |
Family
ID=26694875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003552781A Pending JP2005516938A (ja) | 2001-12-13 | 2002-12-13 | イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6933315B2 (https=) |
| EP (1) | EP1458734B1 (https=) |
| JP (1) | JP2005516938A (https=) |
| AT (1) | ATE484514T1 (https=) |
| AU (1) | AU2002357191A1 (https=) |
| CA (1) | CA2469649C (https=) |
| DE (1) | DE60237993D1 (https=) |
| WO (1) | WO2003051900A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US20100098702A1 (en) * | 2008-09-16 | 2010-04-22 | Longgui Wang | Method of treating androgen independent prostate cancer |
| US8748475B2 (en) | 2004-01-12 | 2014-06-10 | Natrogen Therapeutics International, Inc. | Methods and compositions for treating lupus |
| CN101074229B (zh) * | 2007-06-08 | 2010-09-01 | 无锡杰西医药科技有限公司 | 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途 |
| CN101426268B (zh) * | 2007-11-02 | 2010-08-25 | 大唐移动通信设备有限公司 | 导频资源分配方法、系统和设备 |
| US8563595B2 (en) * | 2008-11-14 | 2013-10-22 | Board Of Regents, The University Of Texas System | Treatment of cancer with complex organic-inorganic pigment compositions |
| US20150087687A1 (en) * | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CN110123763A (zh) * | 2012-06-21 | 2019-08-16 | 法斯瑞斯公司 | 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 |
| CN103333161B (zh) * | 2013-05-28 | 2015-09-30 | 滁州市洛达生物科技有限公司 | 1’-氧代靛玉红的制备和用途 |
| CN110740991B (zh) | 2017-05-26 | 2023-07-04 | 大鹏药品工业株式会社 | 新型联苯化合物或其盐 |
| JP6738962B2 (ja) * | 2017-05-26 | 2020-08-12 | 大鵬薬品工業株式会社 | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 |
| US12435128B2 (en) | 2017-05-31 | 2025-10-07 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| WO2020117487A1 (en) * | 2018-12-07 | 2020-06-11 | Natrogen Therapeutics International, Inc. | Polymorphic form of meisoindigo and modified formulation of meisoindigo |
| MX2022005812A (es) | 2019-11-13 | 2022-08-16 | Taiho Pharmaceutical Co Ltd | Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. |
| US11345818B1 (en) | 2020-12-29 | 2022-05-31 | Industrial Technology Research Institute | Dye for fiber and dyeing method |
| WO2022232243A1 (en) * | 2021-04-27 | 2022-11-03 | Curapep Llc | Compositions for wound relief and inhibiting a phd protein and methods of treatment |
| CN114920728B (zh) * | 2022-05-27 | 2023-10-20 | 中南大学 | 一种甲异靛衍生物及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617254A (ja) * | 1984-06-20 | 1986-01-13 | Isukura Sangyo Kk | ビスインドリノンおよびそれを主成分とする制癌剤 |
| US5696092A (en) * | 1995-03-07 | 1997-12-09 | George Washington University | Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers |
| JP2002516851A (ja) * | 1998-05-29 | 2002-06-11 | ゲルハルト アイゼンブランド | サイクリン依存性キナーゼを阻害する医薬製造のためのインジゴイドビスインドール誘導体の使用 |
| HRP20010735A2 (en) * | 1999-04-12 | 2002-12-31 | Gerhard Eisenbrand | Indigoid bisindole derivatives |
| EP1218004B1 (en) * | 1999-04-12 | 2009-04-08 | Heinz Herbert Fiebig | 5-methyl indirubin for use in the treatment of human solid tumors |
-
2002
- 2002-12-13 CA CA2469649A patent/CA2469649C/en not_active Expired - Lifetime
- 2002-12-13 WO PCT/US2002/039866 patent/WO2003051900A1/en not_active Ceased
- 2002-12-13 DE DE60237993T patent/DE60237993D1/de not_active Expired - Lifetime
- 2002-12-13 AU AU2002357191A patent/AU2002357191A1/en not_active Abandoned
- 2002-12-13 EP EP02805123A patent/EP1458734B1/en not_active Expired - Lifetime
- 2002-12-13 AT AT02805123T patent/ATE484514T1/de not_active IP Right Cessation
- 2002-12-13 JP JP2003552781A patent/JP2005516938A/ja active Pending
-
2004
- 2004-06-10 US US10/864,458 patent/US6933315B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516938A5 (https=) | ||
| US12234242B2 (en) | Radiopharmaceuticals, radioimaging agents, and uses thereof | |
| CA2469649A1 (en) | Derivatives of isoindigo, indigo and indirubin and use in treating cancer | |
| EP2393827B1 (en) | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens | |
| EP2268604B1 (en) | Therapies for cancer using isotopically substituted lysine | |
| HUT59370A (en) | Chelating agents for complex formation with radioactive isotopes, their metal complexes and the use thereof for diagnostic and therapeutic purposes | |
| HK1221712A1 (zh) | 雄激素受体调节剂的酯衍生物及其使用方法 | |
| US9125946B2 (en) | Halogenated phenols for diagnostics, antioxidant protection and drug delivery | |
| WO2016141458A1 (en) | Bisphenol ether derivatives and methods for using the same | |
| WO2018045450A1 (en) | Bisphenol a compounds and methods for treating drug-resistant androgen receptor mediated cancers | |
| CN110461836B (zh) | 一种选择性抑制激酶化合物及其用途 | |
| NZ726348A (en) | Androgen receptor modulators and methods for their use | |
| TW593328B (en) | Proactive antitumor compounds | |
| CN105949149B (zh) | 用于治疗或预防乳腺癌的化合物 | |
| CN111454288A (zh) | 含酚羟基的亚膦酰胺、制备方法及其应用 | |
| WO2024230728A1 (zh) | 靶向成纤维细胞活化蛋白的配体 | |
| CN117986320A (zh) | 一种靶向降解细胞内bcl-3的protac化合物及其制备方法与应用 | |
| KR20240161853A (ko) | 신규한 화합물 및 이의 간암 치료 용도 | |
| CN1122132A (zh) | 配位体及其金属配合物 | |
| CN102746315A (zh) | 一种10-11c -甲氧基喜树碱的制备方法及用途 | |
| CN114702544B (zh) | 一种氨基甾体化合物及其制备方法和应用 | |
| CN112194673A (zh) | 一种联合抗肿瘤化合物及其制备方法和应用 | |
| JPS5874641A (ja) | デカルボキシラ−ゼを阻害するフツ素化アルカンジアミン誘導体 | |
| CN101289421A (zh) | 烟酰氨基酸类化合物的合成方法及其对肿瘤放疗的增敏作用 | |
| US10220100B2 (en) | Halogenated phenols for diagnostics, antioxidant protection and drug delivery |